Mammen Mathai
Officer at TXG; SVP, Research & Early Clin Dev at INVA
- Sold, on record
- $4.7M
- Dollars the filings state
- Form 4 sales
- 9
- Latest May 11, 2023
- Form 144 notices
- 1
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale INVAPlan not statedAug 13, 2012 2012
Sold 25,000 shares at $25.74 ($643k)
Mammen Mathai, SVP, Research & Early Clin Dev
Sold 10.5% of holdings ($6.1M position)212,285 shares leftFiling
- 2 Form 4 sale INVAPlan not statedNov 2, 2012 +81 days
Sold 7,000 shares at $21.45 ($150k)
Mammen Mathai, SVP, Research & Early Clin Dev
Sold 3.3% of holdings ($4.6M position)205,641 shares leftFiling
- 3 Form 4 sale INVAPlan not statedFeb 20, 2013 +110 days
Sold 7,000 shares at $22.14 ($155k)
Mammen Mathai, SVP, Research & Early Clin Dev
Sold 3.2% of holdings ($4.9M position)212,976 shares leftFiling
- 4 Form 4 sale INVAPlan not statedApr 30, 2013 +69 days
Sold 7,000 shares at $33.74 ($236k)
Mammen Mathai, SVP, Research & Early Clin Dev
Sold 3.3% of holdings ($7.2M position)205,976 shares left1x usual sizeFiling
- 5 Form 4 sale INVAPlan not statedJul 30, 2013 +91 days
Sold 7,000 shares at $36.51 ($256k)
Mammen Mathai, SVP, Research & Early Clin Dev
Sold 3.2% of holdings ($8M position)211,705 shares left1x usual sizeFiling
- 6 Form 4 sale INVAUnusualFeb 14, 2014 +199 days
Sold 35,000 shares at $39.36 ($1.4M)
Mammen Mathai, SVP, Research & Early Clin Dev
Sold 15.8% of holdings ($8.7M position)186,623 shares left5x usual sizeFiling
- 7 Form 144 notice TXGNoticeMay 11, 2023 +3373 days
Filed to sell 33,000 shares ($1.8M)
Mammen Mathai, Officer
No 10b5-1 planFirst sale on recordFiling
- 8 Form 4 sale TXGNo planMay 11, 2023 same day
Sold 33,000 shares at $52.82 ($1.7M)
Mammen Mathai, Director
No 10b5-1 planSold 16.3% of holdings ($10.7M position)169,745 shares leftFirst sale on recordFollows a Form 144Filing
Every transaction
Loading transactions…
Sales and notices (10)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| May 11, 2023 | May 15, 2023 | TXG | Director | Form 4 sale | 33,000 | $1.7M | 16.3% | No plan | SEC |
| May 11, 2023 | May 11, 2023 | TXG | Officer | Form 144 notice | 33,000 | $1.8M | Notice | SEC | |
| Feb 14, 2014 | Feb 19, 2014 | INVA | SVP, Research & Early Clin Dev | Form 4 sale | 35,000 | $1.4M | 15.8% | Unusual | SEC |
| Jul 30, 2013 | Aug 1, 2013 | INVA | SVP, Research & Early Clin Dev | Form 4 sale | 7,000 | $256k | 3.2% | Plan not stated | SEC |
| Apr 30, 2013 | May 2, 2013 | INVA | SVP, Research & Early Clin Dev | Form 4 sale | 7,000 | $236k | 3.3% | Plan not stated | SEC |
| Feb 20, 2013 | Feb 22, 2013 | INVA | SVP, Research & Early Clin Dev | Form 4 sale | 7,000 | $155k | 3.2% | Plan not stated | SEC |
| Nov 2, 2012 | Nov 6, 2012 | INVA | SVP, Research & Early Clin Dev | Form 4 sale | 7,000 | $150k | 3.3% | Plan not stated | SEC |
| Aug 13, 2012 | Aug 15, 2012 | INVA | SVP, Research & Early Clin Dev | Form 4 sale | 25,000 | $643k | 10.5% | Plan not stated | SEC |
| Feb 18, 2011 | Feb 23, 2011 | INVA | SVP, Research & Early Clin Dev | Form 4 sale | 3,701 | $86k | 1.4% | Plan not stated | SEC |
| Sep 1, 2010 | Sep 2, 2010 | INVA | SVP, Research & Early Clin Dev | Form 4 sale | 4,416 | $57k | 3.6% | Plan not stated | SEC |